Related Experiment Video
Updated: Apr 21, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Febrile seizure recurrence reduced by intermittent oral levetiracetam
Lin-Yan Hu1, Li-Ping Zou1, Jian-Min Zhong2
1Department of Pediatrics, Chinese PLA General Hospital Beijing, 100583, China ; Department of Pediatrics, Chinese PLA General Hospital Beijing, 100583, China.
Insights
Levetiracetam (LEV) effectively prevents febrile seizure (FS) recurrence in children. This treatment is also more cost-effective and has minimal side effects compared to standard care.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Febrile seizures (FS) are the most common childhood seizure disorder and a frequent reason for pediatric emergency admissions.
- Identifying effective and safe therapies to prevent FS recurrence is a significant clinical challenge.
Purpose of the Study:
- To evaluate the efficacy and safety of intermittent oral levetiracetam (LEV) for preventing febrile seizure recurrence in children.
- To assess the cost-effectiveness of LEV compared to a control group.
Main Methods:
- A randomized controlled trial involving 115 children with a history of two or more FS.
- Participants were assigned to receive either levetiracetam (LEV) or a control (2:1 ratio).
- LEV was administered orally at 15-30 mg/kg/day for one week at fever onset, followed by a gradual taper.
Main Results:
- The LEV group showed a significantly lower FS recurrence rate (11/78 children) compared to the control group (19/37 children).
- LEV treatment was associated with a lower FS recurrence per fever episode.
- The cost of preventing FS recurrence with LEV was lower than the control group.
- The primary side effect observed was mild drowsiness in one patient.
Conclusions:
- Intermittent oral levetiracetam is an effective strategy for preventing febrile seizure recurrence in children.
- LEV therapy offers a cost-effective solution, reducing medical resource expenditure.
- The treatment demonstrates a favorable safety profile with minimal adverse effects.
Objective:
Febrile seizure (FS) is the most common form of childhood seizure disorders. FS is perhaps one of the most frequent causes of admittance to pediatric emergency wards worldwide. We aimed to identify a new, safe, and effective therapy for preventing FS recurrence.
Methods:
A total of 115 children with a history of two or more episodes of FS were randomly assigned to levetiracetam (LEV) and control (LEV/control ratio = 2:1) groups. At the onset of fever, LEV group was orally administered with a dose of 15-30 mg/kg per day twice daily for 1 week. Thereafter, the dosage was gradually reduced until totally discontinued in the second week. The primary efficacy variable was seizure frequency associated with febrile events and FS recurrence rate (RR) during 48-week follow-up. The second outcome was the cost effectiveness of the two groups.
Results:
The intention-to-treat analysis showed that 78 children in LEV group experienced 148 febrile episodes. Among these 78 children, 11 experienced 15 FS recurrences. In control group, 37 children experienced 64 febrile episodes; among these 37 children, 19 experienced 32 FS recurrences. A significant difference was observed between two groups in FS RR and FS recurrence/fever episode. The cost of LEV group for the prevention of FS recurrence is lower than control group. During 48-week follow-up period, one patient in LEV group exhibited severe drowsiness. No other side effects were observed in the same patient and in other children.
Interpretation:
Intermittent oral LEV can effectively prevent FS recurrence and reduce wastage of medical resources.
More Related Videos
05:33A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
Published on: June 23, 2022
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures l: Introduction
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures ll: Types